Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the Netherlands / NCT06046950
Active, not recruiting Not applicable

TrEatment Targets in Rheumatoid Arthritis: TETRA-study

NCT06046950 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Sint Maartenskliniek
Phase
Not applicable
Started
2023-12-20
Last updated
2025-09-11

Condition(s) studied

Rheumatoid Arthritis

Investigational drug(s) / intervention(s)

Treatment target DAS28CRP-LDATreatment target SDAI-remission

Treatment target DAS28CRP-LDA: Aiming for DAS28CRP-low disease activity

Treatment target SDAI-remission: Aiming for SDAI-remission

Study summary

There is currently no cure for rheumatoid arthritis (RA), but many treatment options are available. The central aim of RA treatment is lowering disease activity. The proactive treatment strategy called treat to target (T2T) includes measuring disease activity, setting a target and adjusting treatment accordingly until the goal is reached. T2T has proven to be superior to usual care, but there is much debate regarding the most optimal treatment measure and target. The Disease Activity Score with 28-joint counts and c-reactive protein (DAS28CRP) low-disease activity (LDA) target and the more stringent Simplified Disease Activity Index (SDAI) remission target are the best validated targets. Especially the DAS28CRP is the most commonly used in research and practice, whereas the SDAI remission target is most recommended. The European Alliance of Associations for Rheumatology (EULAR) recommends to strive for remission, whereas the American College of Rheumatology (ACR) recommends to strive for LDA. In patients with new and established RA, the (cost)effectiveness of aiming for remission compared to LDA when starting and tapering antirheumatic drugs has not been directly compared. This study therefore aims to directly compare two T2T strategies, aiming at DAS28CRP-LDA and SDAI remission, in patients with established RA.

Eligibility

Sex
ALL
Min age
16 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of RA (according to the 2010 or 1987 ACR/ EULAR classification criteria and/or clinical diagnosis) * (Starting) use of a DMARD * Aged 16 years or older * At most low disease activity, operationalised as DAS28-CRP \<3.5 (DAS28 CRP 2.9 cut off for low disease activity with measurement error 0.6) or SDAI \<19 (SDAI 11 cut off for low disease activity with measurement error of 8). A state of low disease activity is required at inclusion, as for RA patients in moderate or high disease activity there is no equipoise on the best course of action (treatment needs to be escalated). * Fluency of Dutch or English, both written and verbally; able to fill in questionnaires * Provided informed consent Exclusion Criteria: * Clinical deep remission, operationalised as SDAI \<3.3 or DAS28-CRP \<2.4, and an taper attempt in the past 2 years that was discontinued due to occurrence of flare. * Fewer than 3 DMARD treatment options left for this patient (severe difficult-to-treat or refractory RA) * Current severe comorbidity or other serious life-shortening conditions hampering trial participation * Inability to comply with the study protocol or to provide informed consent with regard to intervention control and measuring outcomes

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sint Maartenskliniek Ubbergen Netherlands

More Sint Maartenskliniek trials in the Netherlands

REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases Recruiting
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse Active, not recruiting
Discontinuation of Disease-modifying Anti-rheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients Also Using TNF Inhibitors Recruiting
The Effect of ColcHicine on the Incidence of Knee or Hip Replacements Recruiting
The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis Recruiting

Other trials for the same condition

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis Active, not recruiting
The ATtune Knee Outcome Study Recruiting
G7 BiSpherical Acetabular Shell PMCF Study Active, not recruiting
Zimmer POLAR Persona - TKA (EMEA Study) Active, not recruiting
ConsideRAte Study - Splenic Stimulation for RA Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06046950 on ClinicalTrials.gov ↗ ← All trials in the Netherlands